It’s the future. You don’t export reports. You don’t log into five portals. You don’t scroll through tabs to find expired licenses. You ask your system: “Show me the DSCSA
ORLANDO, February 25, 2025 – TrackTraceRX, a leading provider of innovative track-and-trace solutions specializing in end-to-end visibility for the pharmaceutical supply chain, is pleased to announce a new strategic partnership
With the final exemption deadline approaching in May 2025, manufacturers must take critical steps to meet the interoperability, serialization, and traceability requirements outlined by the FDA. If you’re not prepared,
The Drug Supply Chain Security Act (DSCSA) compliance deadlines are fast approaching, and despite recent political shifts, these deadlines remain firmly in place. The Trump administration’s regulatory freeze, introduced in
Welcome to 2025—a game-changing year for the pharmacy industry. With DSCSA requirements reaching full implementation, the landscape is changing rapidly. On October 9, 2024, the FDA issued new guidance, offering
TrackTraceRX, a leading provider of innovative track-and-trace solutions, specializing in end-to-end visibility for the pharmaceutical supply chain, and Omnicell, Inc. (Nasdaq: OMCL), a leader in transforming the pharmacy care delivery
Following National Pharmacy Week in October, which celebrated pharmacies’ critical role in patient care, the focus now shifts to compliance. With the Drug Supply Chain Security Act (DSCSA) deadline nearing
The Drug Supply Chain Security Act (DSCSA) is a critical regulation aimed at ensuring that drug products are tracked and traced electronically across the supply chain. On October 9, 2024, the
The recent announcement from the FDA has sent waves through the pharmaceutical industry, reinforcing the urgency of the Drug Supply Chain Security Act (DSCSA) compliance. Patrizia Cavazzoni, Director of the
Read 5 strategies to help safeguard the pharmaceutical supply chain from counterfeit drugs.
Shaping the future of traceability and serialization since 2007
